RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Evofem Biosciences Stock

Evofem Biosciences ROA 2024

Evofem Biosciences ROA

4.74

Ticker

EVFM

ISIN

US30048L1044

WKN

A2JBZC

In 2024, Evofem Biosciences's return on assets (ROA) was 4.74, a -252.79% increase from the -3.1 ROA in the previous year.

Evofem Biosciences Aktienanalyse

What does Evofem Biosciences do?

Evofem Biosciences Inc is a biochemistry company based in San Diego, California, that focuses on developing products to enhance women's sexual and reproductive health. The company, founded in 2001 by a group of scientists and doctors, aims to provide women with more effective methods of contraception and treatment for infectious diseases. Evofem Biosciences is an innovative biotech company specializing in the development of women's lifestyle and healthcare products, with a focus on birth control and the prevention of sexually transmitted infections (STIs). These products are developed using the company's own technology, which is based on a novel chemical binder and has proven to be particularly effective and safe. Evofem Biosciences' products are used by women around the world to protect themselves against unintended pregnancy and STIs. In the United States, the company is known as the only one that exclusively focuses on the development and marketing of women's products. The current products of Evofem Biosciences primarily focus on contraception. For example, the company has developed and markets a vaginal gel called "Phexxi." Phexxi is a hormone-free contraceptive that is used as needed to block sperm from reaching the egg. It was designed to provide women with a new option for contraception when hormonal contraceptives are not suitable due to side effects or other reasons. Another product in Evofem Biosciences' pipeline is an antimicrobial gel developed for the prevention of STIs, including chlamydia and gonorrhea. The gel is based on the same technology as Phexxi and is currently in phase III of clinical trials. Evofem Biosciences also operates a clinical research department focused on reproductive health and oncology, including breast cancer. This research aims to develop new diagnostic procedures and therapies to improve outcomes for women worldwide. Overall, Evofem Biosciences is a company that focuses on the needs of women and holds a leading position in the industry. Since its founding, the company has maintained its focus and goals, successfully developing and bringing innovative products to market over the past 20 years. It is expected that the company will continue to bring products to market in the future that meet the needs of women worldwide and definitively contribute to improving their sexual and reproductive health. Evofem Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Evofem Biosciences's Return on Assets (ROA)

Evofem Biosciences's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Evofem Biosciences's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Evofem Biosciences's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Evofem Biosciences’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Evofem Biosciences stock

What is the Return on Assets (ROA) of Evofem Biosciences this year?

The Return on Assets (ROA) of Evofem Biosciences is 4.74 undefined this year.

What was the ROA of Evofem Biosciences compared to the previous year?

The ROA of Evofem Biosciences has increased by -252.79% compared to the previous year.

What consequences do high ROA have for investors of Evofem Biosciences?

A high ROA is advantageous for investors of Evofem Biosciences, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Evofem Biosciences?

A low ROA can be unfavorable for investors of Evofem Biosciences as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Evofem Biosciences affect the company?

An increase in ROA of Evofem Biosciences can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Evofem Biosciences impact the company?

A reduction in the ROA of Evofem Biosciences can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Evofem Biosciences?

Some factors that can influence the ROA of Evofem Biosciences include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Evofem Biosciences important for investors?

The ROA of Evofem Biosciences is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Evofem Biosciences take to improve ROA?

To improve ROA, Evofem Biosciences can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Evofem Biosciences pay?

Over the past 12 months, Evofem Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Evofem Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Evofem Biosciences?

The current dividend yield of Evofem Biosciences is .

When does Evofem Biosciences pay dividends?

Evofem Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Evofem Biosciences?

Evofem Biosciences paid dividends every year for the past 0 years.

What is the dividend of Evofem Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Evofem Biosciences located?

Evofem Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Evofem Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Evofem Biosciences from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did Evofem Biosciences pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of Evofem Biosciences in the year 2023?

In the year 2023, Evofem Biosciences distributed 0 USD as dividends.

In which currency does Evofem Biosciences pay out the dividend?

The dividends of Evofem Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Evofem Biosciences

Our stock analysis for Evofem Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Evofem Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.